BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug ...

When an insurance denial blocks guest writer Denise Schnieders from getting an MS disease activity test, she decides to fight back.

The court agreed on a block for early generics of a widely prescribed MS treatment, finding even though a psoriasis ...

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...

Learn how early diagnosis and modern therapies can prevent Multiple Sclerosis from leading to long-term disability.

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of ...

New research suggests that Epstein-Barr virus may actively provoke the immune system in people with multiple sclerosis. Scientists found large buildups of virus-targeting immune cells in the nervous ...

An international research team has gained new insights into the dynamics of myelin swellings in the brain. Myelin swellings ...

Investigators have identified patients who tested positive for the Epstein-Barr Virus 9 years after they were diagnosed with MS, challenging the prevailing notion that the virus precedes MS.

Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...